(Q48285752)

10 February 2018

title

Effect of selegiline on dopamine concentration in the striatum of a primate (English)

1 reference

10 February 2018

1 reference

Kaseda S

1

1 reference

10 February 2018

Nomoto M

series ordinal

2

1 reference

10 February 2018

Iwata S

series ordinal

3

1 reference

10 February 2018

language of work or name

English

0 references

publication date

1 January 1999

1 reference

10 February 2018

published in

Brain Research

1 reference

10 February 2018

volume

815

1 reference

10 February 2018

issue

1

1 reference

10 February 2018

page(s)

44-50

1 reference

10 February 2018

Implications of combined treatment with 'Madopar' and L-deprenil in Parkinson's disease. A long-term study

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2898%2901089-0

The potentiation of the anti akinetic effect after L-Dopa treatment by an inhibitor of Mao-B, deprenil

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2898%2901089-0

In vivo comparison of the effects of inhibition of MAO-A versus MAO-B on striatal L-DOPA and dopamine metabolism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2898%2901089-0

Monoamine oxidase-dependent metabolism of dopamine in the striatum and substantia nigra of L-DOPA-treated monkeys.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2898%2901089-0

The effect of age on the activity and molecular properties of human brain monoamine oxidase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2898%2901089-0

Dopamine is a monoamine oxidase B substrate in man.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2898%2901089-0

Some observations upon a new inhibitor of monoamine oxidase in brain tissue.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2898%2901089-0

The possible mechanisms of action of (-)deprenyl in Parkinson's disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2898%2901089-0

Neuroprotective therapy for Parkinson's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2898%2901089-0

[3H]harman binding experiments. II: Regional and subcellular distribution of specific [3H]harman binding and monoamine oxidase subtypes A and B activity in marmoset and rat.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2898%2901089-0

A selective MAOB inhibitor Ro19-6327 potentiates the effects of levodopa on parkinsonism induced by MPTP in the common marmoset

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2898%2901089-0

Monoamine oxidases of the brains and livers of macaque and cercopithecus monkeys

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2898%2901089-0

Effects of selective monoamine oxidase inhibitors on the in vivo release and metabolism of dopamine in the rat striatum.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2898%2901089-0

Deprenil: loss of selectivity for inhibition of B-type MAO after repeated treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2898%2901089-0

Monoamine oxidase activity and distribution in marmoset brain: implications for MPTP toxicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2898%2901089-0

Effect of long-term treatment with selective monoamine oxidase A and B inhibitors on dopamine release from rat striatum in vivo.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2898%2901089-0

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0006-8993(98)01089-0

1 reference

10 February 2018

1 reference

10 February 2018